Amarantus Bioscience Holdings Inc
OTC:AMBS
Operating Margin
Amarantus Bioscience Holdings Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Amarantus Bioscience Holdings Inc
OTC:AMBS
|
368.4 USD | N/A | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.8B USD |
31%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
155.1B USD |
31%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
148.3B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
93.9B USD |
39%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
127.6B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
59.9B USD |
29%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
57.5B USD |
-7%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Amarantus Bioscience Holdings Inc
Glance View
Amarantus BioScience Holdings, Inc. is a biopharmaceutical company. The company is headquartered in San Francisco, California. The company went IPO on 2008-09-29. The firm has approximately three operating divisions: the diagnostics division, the therapeutics division and the drug discovery division. The company owns licenses to various product candidates in the therapeutic and diagnostic sectors of the life sciences industry. The company is developing diagnostic product candidates in the field of neurology, and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company, through its subsidiary, Cutanogen Corporation, is developing a regenerative medicine cell therapy-based autologous skin replacement product, Engineered Skin substitute, which is in mid-stage clinical development, for the treatment of life-threatening severe burns. The company is also developing a mid-stage clinical-stage pharmaceutical drug candidate, Eltoprazine, a small molecule 5HT1a/1b partial agonist for the treatment of symptomatic neurological disorders.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Amarantus Bioscience Holdings Inc's most recent financial statements, the company has Operating Margin of 0%.
You don't have any saved screeners yet